Annual report for Bliss GVS Pharma Ltd. for FY-2019
20-05-2019
Bliss GVS Pharma Ltd - 506197 - Board recommends Dividend (AGM on Sep 20, 2019)
Bliss GVS Pharma Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 18, 2019, inter alia, has recommended a dividend of Re. 1/- per equity share of face value of Rs. 10/- each for the financial year ended March 31, 2019, subject to approval of the shareholders in the ensuing Annual General Meeting (AGM) of the Company.19-05-2019
Bliss GVS Pharma Ltd - 506197 - Outcome of Board Meeting
We would like to inform you that Board Meeting of the Company was held today i.e. on Saturday, May 18, 2019 at registered office of the Company. In pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters as per attachement.18-05-2019
BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Saturday, May 18, 2019 at the registered office of the Company at 4.00 p.m., inter-alia, to consider and approve the audited Standalone and Consolidated Financial Statements and Results of the Company for the quarter and financial year ended March 31, 2019 and recommend a dividend, if any, for the financial year ended March 31, 2019 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshkati' a Regional Daily, on May 11, 2019. Kindly take the same on record.16-05-2019
Bliss GVS Pharma Ltd - 506197 - Board Meeting Intimation for Approval Of Standalone And Consolidation Financial Results For The Quarter And Financial Year Ended On March 31, 2019 And Recommendation Of A Dividend
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2019 ,inter alia, to consider and approve the following: a) the audited Standalone and Consolidated Financial Statements and Results of the Company for the quarter and financial year ended March 31, 2019; and b) recommend a dividend, if any, for the financial year ended March 31, 2019. Further, pursuant to SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from April 04, 2019 and will open after the expiry of 48 hours from declaration of the said financial results i.e. May 20, 2019. Kindly acknowledge and take on record the same.10-05-2019
BLISS GVS PHARMA LTD. - 506197 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBLISS GVS PHARMA LTD. 2CININE416D01022 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 35 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Aditi Bhatt Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Vipul B. Thakkar Designation: Chief Financial Officer EmailId: [email protected] Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2019
Bliss GVS Pharma Ltd - 506197 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2019. Kindly take the same on record.24-04-2019
Bliss GVS Pharma Ltd - 506197 - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2019
Please find enclosed herewith the half yearly compliance certificate issued by Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2019. Kindly take the same on record.24-04-2019
BLISS GVS PHARMA LTD. - 506197 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Year Ended March 31, 2019
Please find enclosed herewith a certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2019. Kindly take the same on record.22-04-2019
Bliss GVS Pharma Ltd - 506197 - Shareholding for the Period Ended March 31, 2019
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here20-04-2019